EGFR/HER2-IN-4 exhibits potent in vivo antitumor efficacy and can be used in lung cancer research; it is an orally active, irreversible dual inhibitor of EGFR and HER2, showing effective inhibition against EGFR kinase activity with an IC50 of 0.6 nM, particularly against L858R and T790M mutations.